Zacks Research Issues Negative Forecast for UTHR Earnings

Key Points

• Zacks Research has revised its Q4 2025 earnings estimate for United Therapeutics from $6.30 to $6.15 per share, while the consensus for the current full year is $24.48 per share.
• Analysts have provided mixed ratings on United Therapeutics, with a recent price target from HC Wainwright at $400.00 and a downgrade by Bank of America to $315.00.
• United Therapeutics' recent quarterly earnings reported $6.41 per share, missing estimates and reflecting a 11.7% year-over-year revenue increase.

United Therapeutics Corporation (NASDAQ:UTHR - Free Report) - Stock analysts at Zacks Research lowered their Q4 2025 earnings estimates for United Therapeutics in a research report issued on Wednesday, August 20th. Zacks Research analyst Team now forecasts that the biotechnology company will post earnings of $6.15 per share for the quarter, down from their prior forecast of $6.30. The consensus estimate for United Therapeutics' current full-year earnings is $24.48 per share. Zacks Research also issued estimates for United Therapeutics' Q1 2026 earnings at $7.08 EPS.

A number of other analysts have also recently weighed in on UTHR. HC Wainwright set a $400.00 price target on United Therapeutics and gave the stock a "buy" rating in a research report on Thursday, July 31st. Bank of America dropped their target price on United Therapeutics from $321.00 to $315.00 and set a "neutral" rating on the stock in a research report on Wednesday, June 11th. Wells Fargo & Company reduced their price target on shares of United Therapeutics from $314.00 to $295.00 and set an "equal weight" rating for the company in a report on Thursday, July 31st. Morgan Stanley dropped their price objective on shares of United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating on the stock in a report on Thursday, July 10th. Finally, UBS Group lifted their price objective on shares of United Therapeutics from $385.00 to $415.00 and gave the company a "buy" rating in a research report on Wednesday, August 13th. Nine equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $382.00.

United Therapeutics Stock Up 0.5%

Shares of NASDAQ UTHR opened at $312.23 on Monday. The firm's 50-day moving average price is $297.01 and its two-hundred day moving average price is $307.02. United Therapeutics has a 52-week low of $266.98 and a 52-week high of $417.82. The stock has a market capitalization of $14.08 billion, a P/E ratio of 12.19, a P/E/G ratio of 4.73 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing the consensus estimate of $6.80 by ($0.39). The business had revenue of $798.60 million during the quarter, compared to analyst estimates of $802.13 million. United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The company's quarterly revenue was up 11.7% on a year-over-year basis. During the same period last year, the firm posted $5.85 earnings per share.

Hedge Funds Weigh In On United Therapeutics

Several hedge funds have recently modified their holdings of UTHR. Dunhill Financial LLC lifted its holdings in shares of United Therapeutics by 100.0% in the fourth quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company's stock valued at $35,000 after buying an additional 50 shares during the period. Chung Wu Investment Group LLC acquired a new stake in United Therapeutics in the 2nd quarter valued at about $29,000. SVB Wealth LLC bought a new position in shares of United Therapeutics during the 1st quarter valued at about $32,000. WealthCollab LLC grew its stake in shares of United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock worth $30,000 after purchasing an additional 38 shares during the last quarter. Finally, Rakuten Securities Inc. raised its holdings in shares of United Therapeutics by 76.7% in the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company's stock worth $30,000 after purchasing an additional 46 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at United Therapeutics

In other United Therapeutics news, Director Richard Giltner sold 3,036 shares of the business's stock in a transaction dated Tuesday, June 24th. The shares were sold at an average price of $289.60, for a total transaction of $879,225.60. Following the sale, the director directly owned 19,384 shares in the company, valued at approximately $5,613,606.40. The trade was a 13.54% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Paul A. Mahon sold 11,000 shares of the company's stock in a transaction that occurred on Thursday, June 12th. The stock was sold at an average price of $279.96, for a total transaction of $3,079,560.00. Following the completion of the sale, the executive vice president directly owned 36,781 shares of the company's stock, valued at approximately $10,297,208.76. This represents a 23.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 92,681 shares of company stock worth $28,014,609. 10.30% of the stock is currently owned by corporate insiders.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.